Emerging Gene Delivery Technologies for Advancing Molecular Medicine and Gene Therapy

Veronese Dwan^*
*Correspondence: Veronese Dwan, Department of Science, Mansoura University, El Gomhouria St, Dakahlia Governorate 35516, Egypt, Email:

Introduction

Gene therapy has emerged as a promising approach in the field of molecular medicine, offering the potential to treat a wide range of genetic and acquired diseases at the genetic level. One of the critical challenges in gene therapy is the efficient and targeted delivery of therapeutic genes to the desired cells and tissues. Over the years, significant progress has been made in developing various gene delivery technologies to overcome these challenges. This review article provides an overview of the emerging gene delivery technologies, including viral and non-viral vectors, nanoparticles, and genome editing tools, highlighting their advantages, limitations, and applications in advancing molecular medicine and gene therapy. Gene therapy involves the introduction, modification, or repair of genetic material within a patient's cells to correct or treat genetic disorders or acquired diseases. The success of gene therapy relies on the efficient and safe delivery of therapeutic genes to target cells while minimizing off-target effects. This article reviews the recent advances in gene delivery technologies that hold the potential to revolutionize molecular medicine and gene therapy [1-3].

Viral vectors have been extensively explored for gene delivery due to their natural ability to enter cells and transfer genetic material. Adeno-associated viruses, lentiviruses, and adenoviruses are commonly used viral vectors. Recent advancements in engineering viral vectors have led to improved targeting, reduced immunogenicity, and enhanced gene expression levels. Challenges associated with viral vectors include potential immune responses and limitations in cargo capacity. Non-viral gene delivery methods, including liposomes, polymers, and naked DNA/RNA, offer safer alternatives to viral vectors. These systems provide better control over cargo size, reduced immunogenicity, and potential for repeated dosing.

Recent developments in nanoparticle-based delivery, such as lipid nanoparticles and polymer-based nanoparticles, have shown enhanced cellular uptake and improved gene delivery efficiency. Genome editing technologies like CRISPR-Cas9 have gained immense popularity for their potential to precisely modify the genetic code. Integrating genome editing tools with gene delivery systems allows for targeted gene correction, disruption, or addition. However, ensuring precise editing and minimizing off-target effects remain challenges that require further optimization.

Description

Exosomes, small extracellular vesicles secreted by cells, have gained attention as natural carriers of genetic material between cells. Engineered exosomes can be loaded with therapeutic genes and targeted to specific cell types, offering a promising avenue for intercellular gene delivery with reduced immune responses. Gene therapy has shown immense promise in treating genetic and acquired diseases by targeting the root cause at the genetic level. However, successful gene therapy relies heavily on efficient and targeted delivery of therapeutic genes to the appropriate cells and tissues. This challenge has driven the development of various gene delivery technologies to ensure safe and effective treatment outcomes.

Emerging gene delivery technologies have enabled innovative applications in molecular medicine and gene therapy. These include treatment of genetic disorders, cancer gene therapy, regenerative medicine, and vaccination strategies. Personalized medicine approaches that leverage gene therapy are also becoming feasible with advancements in targeted delivery methods. While significant progress has been made, challenges such as immunogenicity, offtarget effects, scalability, and regulatory hurdles still need to be addressed for widespread clinical adoption of gene therapy. Future research efforts should focus on refining delivery technologies, improving specificity, and conducting rigorous clinical trials to validate safety and efficacy [4,5].

The reviewed gene delivery technologies offer several advantages over traditional methods, addressing critical challenges that have hindered the success of gene therapy, the development of viral vectors with improved targeting capabilities allows for more precise delivery of therapeutic genes to specific cell types. This is crucial for minimizing off-target effects and maximizing therapeutic efficacy. Non-viral delivery systems, including nanoparticles and liposomes, exhibit lower immunogenicity compared to viral vectors. This characteristic reduces the risk of triggering unwanted immune responses and promotes safer and repeated dosing.

The integration of genome editing tools like CRISPR-Cas9 into gene delivery systems has paved the way for personalized medicine approaches. Patients with specific genetic mutations can benefit from targeted corrections tailored to their individual genetic profiles. The development of advanced gene delivery technologies necessitates interdisciplinary collaborations among researchers in fields such as molecular biology, nanotechnology, and immunology. This collaborative approach accelerates innovation and fosters novel solutions to complex challenges. Gene therapy has the potential to treat a multitude of genetic disorders, including cystic fibrosis, hemophilia, and sickle cell anemia. The ability to precisely introduce functional genes or correct genetic mutations holds promise for alleviating the root causes of these conditions.

Conclusion

The rapid development of emerging gene delivery technologies holds great promise for advancing molecular medicine and gene therapy. Viral and non-viral vectors, genome editing tools, and exosome-mediated delivery are reshaping the landscape of genetic medicine. As these technologies continue to evolve, they have the potential to transform the treatment of a wide range of diseases, ushering in a new era of precision medicine.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Calvo, Margarita, Alexander J. Davies, Harry L. Hebert and Greg A. Weir, et al. "The genetics of neuropathic pain from model organisms to clinical application." Neuron 104 (2019): 637-653.

Google Scholar, Crossref, Indexed at

2. Qiu, Min, Zachary Glass, Jinjin Chen and Mary Haas, et al. "Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3." Proc Natl Acad Sci 118 (2021): e2020401118.

Google Scholar, Crossref, Indexed at

3. Romanov, Georgy A., Sergey N. Lomin and Thomas Schmülling. "Cytokinin signaling: From the ER or from the PM? That is the question!” New Phytologist 218 (2018): 41-53.

Google Scholar, Crossref, Indexed at

4. Keiler, Kenneth C. and Heather A. Feaga. "Resolving nonstop translation complexes is a matter of life or death." J Bacteriol 196 (2014): 2123-2130.

Google Scholar, Crossref, Indexed at

5. Brady, Anna K., Jonathan D. McNeill, Brendan Judy and Joshua Bauml, et al. "Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy." Oncotarget 6 (2015): 30287.

Google Scholar, Crossref, Indexed at